Please login to the form below

Not currently logged in
Email:
Password:

mavacamten

This page shows the latest mavacamten news and features for those working in and with pharma, biotech and healthcare.

Bristol Myers Squibb’s Camzyos recommended by NICE for inherited heart condition

Bristol Myers Squibb’s Camzyos recommended by NICE for inherited heart condition

Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Camzyos (mavacamten) for use across NHS England and Wales in adults with symptomatic

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....